Progress in Neuro-Psychopharmacology & Biological Psychiatry
Progress in Neuro-Psychopharmacology & Biological Psychiatry is a peer-reviewed journal published eight times per year by Elsevier, covering neuropsychopharmacology and biological psychiatry. Founded in 1977, it is an international and multidisciplinary journal ensuring the rapid publication of authoritative reviews and research papers on experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry, with a 2025 impact factor of 4.2, indexed in SCIE.《神经-精神药理学与生物精神病学进展》（Progress in Neuro-Psychopharmacology & Biological Psychiatry, 简称 PNPBP）是由 Elsevier 每年出版八期的同行评审期刊，涵盖神经精神药理学与生物精神病学。该刊创刊于 1977 年，是确保神经-精神药理学与生物精神病学实验与临床方面权威综述与研究论文快速发表的国际多学科期刊，2025 年影响因子为 4.2，被 SCIE 收录。
Scope
The journal's stated aim is to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry, with its official scope covering:刊物官方宗旨为确保神经-精神药理学与生物精神病学实验与临床方面权威综述与研究论文的快速发表，官方声明的征稿范围包括：
- Neuropsychopharmacology: original research on the effects of pharmacological agents on the brain, behavior, and mental processes, including mechanisms of action.神经精神药理学： 关于药物对大脑、行为与心理过程影响的原创研究，包括作用机制。
- Biological psychiatry: studies on the biological basis of psychiatric disorders, including neurochemistry, neuroendocrinology, and genetics.生物精神病学： 关于精神障碍生物学基础的研究，包括神经化学、神经内分泌学与遗传学。
- Psychiatric disorders and treatment: research on the pathophysiology and treatment of mood disorders, schizophrenia, anxiety disorders, and other psychiatric conditions.精神障碍与治疗： 关于情绪障碍、精神分裂症、焦虑障碍及其他精神疾病病理生理学与治疗的研究。
- Translational neuroscience: studies that bridge basic neuroscience research with clinical applications in psychiatry and pharmacology.转化神经科学： 衔接基础神经科学研究与精神病学和药理学临床应用的研究。
- Article types: the journal publishes original research articles, review articles, and brief reports on neuropsychopharmacology and biological psychiatry.栏目设置： 该刊发表神经精神药理学与生物精神病学领域的原创研究论文、综述与短讯。
History
- Founding: the journal was established in 1977 to provide a dedicated publication venue for research at the interface of pharmacology, neuroscience, and psychiatry.创刊： 该刊于 1977 年创刊，为药理学、神经科学与精神病学交叉领域的研究提供专属出版平台。
- Elsevier publication: PNPBP is published by Elsevier, ensuring high editorial standards and broad international distribution.Elsevier 出版： PNPBP 由 Elsevier 出版，确保高编辑标准与广泛的国际传播。
- Multidisciplinary scope: throughout its history, the journal has emphasized the integration of pharmacology, neuroscience, and clinical psychiatry in understanding and treating mental disorders.多学科范围： 在其发展历程中，该刊始终强调整合药理学、神经科学与临床精神病学以理解与治疗精神障碍。
- Publication frequency: the journal publishes eight times per year, ensuring rapid dissemination of important advances in neuropsychopharmacology.出版频率： 该刊每年出版八期，确保神经精神药理学重要进展的快速传播。
Editors
The journal is led by an editor-in-chief supported by an editorial board:该刊由主编领导，编委会协助工作：
- Editor-in-chief: Louis Gendron, PhD of the Université de Sherbrooke, Sherbrooke, Quebec, Canada, serves as the editor-in-chief.主编： 加拿大魁北克省舍布鲁克舍布鲁克大学的路易·让德龙（Louis Gendron, PhD）担任主编。
- Editorial leadership: the editor-in-chief is supported by editorial board members with expertise across major areas of neuropsychopharmacology and biological psychiatry.编辑领导： 主编由具有神经精神药理学与生物精神病学主要领域专长的编委会成员协助。
- Editorial board: the journal has a large international editorial board comprising pharmacologists, neuroscientists, and psychiatrists from leading institutions worldwide.编委会： 该刊拥有大型国际编委会，成员为来自全球顶尖机构的药理学家、神经科学家与精神科医生。
- Open access option: authors can choose to publish open access in this journal, making their articles freely available to readers upon publication in exchange for an article processing charge.开放获取选项： 作者可选择在该刊发表开放获取文章，使论文发表后即向读者免费开放，并支付文章处理费。